ROIVANT SCIENCES LTD. Investing Cash Flow
ROIVANT SCIENCES LTD. (ROIV) reported Investing Cash Flow of $281.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- ROIVANT SCIENCES LTD. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $281.26M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $173.49M, a 83.85% decline year-over-year.
- ROIVANT SCIENCES LTD. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $109.47M, a 75.89% decline year-over-year.
- ROIVANT SCIENCES LTD. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $120.42M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) investing activities for fiscal 2026 was -$682.33M.
- ROIVANT SCIENCES LTD. net cash provided by (used in) investing activities for fiscal 2025 was -$1.77B, a 133.94% decline from fiscal 2024.
- ROIVANT SCIENCES LTD. net cash provided by (used in) investing activities for fiscal 2024 was $5.20B.
- ROIVANT SCIENCES LTD. net cash provided by (used in) investing activities for fiscal 2023 was -$44.27M, a 114.60% decline from fiscal 2022.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $281.26M 10-Q · filed 2026-08-06 | $454.75M derived: sum of 2 quarters · filed 2026-08-06 | $564.22M derived: sum of 3 quarters · filed 2026-08-06 | $684.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $173.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $282.96M derived: sum of 2 quarters · filed 2026-05-20 | $403.38M derived: sum of 3 quarters · filed 2026-05-20 | -$682.33M 10-K · filed 2026-05-20 |
| 2025-12-31 | $109.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | $229.89M derived: sum of 2 quarters · filed 2026-02-06 | -$855.82M 10-Q · filed 2026-02-06 | $218.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $120.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$965.29M 10-Q · filed 2025-11-10 | $108.90M derived: sum of 3 quarters · filed 2026-08-06 | $562.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.09B 10-Q · filed 2026-08-06 | -$11.52M derived: sum of 2 quarters · filed 2026-08-06 | $442.55M derived: sum of 3 quarters · filed 2026-08-06 | -$2.85B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.07B derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $1.53B derived: sum of 2 quarters · filed 2026-05-20 | -$1.77B derived: sum of 3 quarters · filed 2026-05-20 | -$1.77B 10-K · filed 2026-05-20 |
| 2024-12-31 | $454.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | -$2.84B derived: sum of 2 quarters · filed 2026-02-06 | -$2.84B 10-Q · filed 2026-02-06 | -$2.83B derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | -$3.29B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$3.29B 10-Q · filed 2025-11-10 | -$3.29B derived: sum of 3 quarters · filed 2026-05-20 | $1.95B derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | -$965.00K 10-Q · filed 2025-08-11 | $5.96M derived: sum of 2 quarters · filed 2026-05-20 | $5.24B derived: sum of 3 quarters · filed 2026-05-20 | $5.20B derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | $6.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $5.24B derived: sum of 2 quarters · filed 2026-05-20 | $5.20B derived: sum of 3 quarters · filed 2026-05-20 | $5.20B 10-K · filed 2026-05-20 |
| 2023-12-31 | $5.23B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | $5.20B derived: sum of 2 quarters · filed 2025-02-10 | $5.20B 10-Q · filed 2025-02-10 | $5.31B derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | -$36.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | -$36.35M 10-Q · filed 2024-11-12 | $77.21M derived: sum of 3 quarters · filed 2025-05-29 | $73.70M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | $105.00K 10-Q · filed 2024-08-09 | $113.66M derived: sum of 2 quarters · filed 2025-05-29 | $110.15M derived: sum of 3 quarters · filed 2025-05-29 | -$36.70M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | $113.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $110.04M derived: sum of 2 quarters · filed 2025-05-29 | -$36.81M derived: sum of 3 quarters · filed 2025-05-29 | -$44.27M 10-K · filed 2025-05-29 |
| 2022-12-31 | -$3.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | -$150.36M derived: sum of 2 quarters · filed 2024-02-13 | -$157.82M 10-Q · filed 2024-02-13 | -$163.52M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | -$146.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | -$154.31M 10-Q · filed 2023-11-13 | -$160.01M derived: sum of 3 quarters · filed 2023-11-13 | -$166.09M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$7.46M 10-Q · filed 2023-08-14 | -$13.16M derived: sum of 2 quarters · filed 2023-08-14 | -$19.23M derived: sum of 3 quarters · filed 2023-08-14 | $298.18M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | -$11.78M derived: sum of 2 quarters · filed 2023-06-28 | $305.63M derived: sum of 3 quarters · filed 2023-06-28 | $303.30M 10-K · filed 2023-06-28 |
| 2021-12-31 | -$6.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-13 | $311.34M derived: sum of 2 quarters · filed 2023-02-13 | $309.00M 10-Q · filed 2023-02-13 | $304.91M derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-09-30 | $317.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | $315.07M 10-Q · filed 2022-11-14 | $310.98M derived: sum of 3 quarters · filed 2022-11-14 | $310.87M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$2.34M 10-Q · filed 2022-08-15 | -$6.43M derived: sum of 2 quarters · filed 2022-08-15 | -$6.54M derived: sum of 3 quarters · filed 2022-08-15 | -$8.40M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | -$4.20M derived: sum of 2 quarters · filed 2022-06-28 | -$6.06M derived: sum of 3 quarters · filed 2022-06-28 | -$31.70M 10-K · filed 2022-06-28 |
| 2020-12-31 | -$107.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-02-14 | -$1.97M derived: sum of 2 quarters · filed 2022-02-14 | -$27.61M 10-Q · filed 2022-02-14 | |
| 2020-09-30 | -$1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-11-15 | -$27.50M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$25.64M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |